- Home
- VERV vs DHIL Comparison
VERV vs DHIL Comparison
Compare VERV & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- DHIL
- Stock Information
- Founded
- VERV 2018
- DHIL 1990
- Country
- VERV United States
- DHIL United States
- Employees
- VERV N/A
- DHIL 127
- Industry
- VERV Medicinal Chemicals and Botanical Products
- DHIL Investment Managers
- Sector
- VERV Health Care
- DHIL Finance
- Exchange
- VERV Nasdaq
- DHIL Nasdaq
- Market Cap
- VERV 384.2M
- DHIL 392.1M
- IPO Year
- VERV 2021
- DHIL 1995
- Fundamental
- Price
- VERV $11.27
- DHIL $155.56
- Analyst Decision
- VERV Buy
- DHIL
- Analyst Count
- VERV 10
- DHIL 0
- Target Price
- VERV $14.57
- DHIL N/A
- AVG Volume (30 Days)
- VERV 8.0M
- DHIL 70.6K
- Earning Date
- VERV 08-07-2025
- DHIL 07-29-2025
- Dividend Yield
- VERV N/A
- DHIL 3.88%
- EPS Growth
- VERV N/A
- DHIL 0.69
- EPS
- VERV N/A
- DHIL 14.79
- Revenue
- VERV $59,613,000.00
- DHIL $151,916,411.00
- Revenue This Year
- VERV $27.75
- DHIL N/A
- Revenue Next Year
- VERV N/A
- DHIL N/A
- P/E Ratio
- VERV N/A
- DHIL $10.50
- Revenue Growth
- VERV 271.44
- DHIL 9.28
- 52 Week Low
- VERV $2.87
- DHIL $122.32
- 52 Week High
- VERV $11.41
- DHIL $173.25
- Technical
- Relative Strength Index (RSI)
- VERV 83.09
- DHIL 73.94
- Support Level
- VERV $11.16
- DHIL $142.30
- Resistance Level
- VERV $11.34
- DHIL $146.60
- Average True Range (ATR)
- VERV 0.20
- DHIL 3.02
- MACD
- VERV 0.06
- DHIL 1.48
- Stochastic Oscillator
- VERV 97.29
- DHIL 100.00
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.